KR102244500B1 - 서방형 부프레노르핀 제제 - Google Patents

서방형 부프레노르핀 제제 Download PDF

Info

Publication number
KR102244500B1
KR102244500B1 KR1020197009185A KR20197009185A KR102244500B1 KR 102244500 B1 KR102244500 B1 KR 102244500B1 KR 1020197009185 A KR1020197009185 A KR 1020197009185A KR 20197009185 A KR20197009185 A KR 20197009185A KR 102244500 B1 KR102244500 B1 KR 102244500B1
Authority
KR
South Korea
Prior art keywords
buprenorphine
pharmaceutical composition
injectable pharmaceutical
acyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197009185A
Other languages
English (en)
Korean (ko)
Other versions
KR20190052021A (ko
Inventor
통-호 린
융-순 원
주이-위 리앙
Original Assignee
에일러 파마슈티컬스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에일러 파마슈티컬스 아이엔씨. filed Critical 에일러 파마슈티컬스 아이엔씨.
Publication of KR20190052021A publication Critical patent/KR20190052021A/ko
Application granted granted Critical
Publication of KR102244500B1 publication Critical patent/KR102244500B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197009185A 2016-09-13 2017-09-12 서방형 부프레노르핀 제제 Active KR102244500B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394168P 2016-09-13 2016-09-13
US62/394,168 2016-09-13
PCT/CN2017/101327 WO2018050043A1 (en) 2016-09-13 2017-09-12 Sustained-release buprenorphine formulations background of invention

Publications (2)

Publication Number Publication Date
KR20190052021A KR20190052021A (ko) 2019-05-15
KR102244500B1 true KR102244500B1 (ko) 2021-04-26

Family

ID=61619029

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197009185A Active KR102244500B1 (ko) 2016-09-13 2017-09-12 서방형 부프레노르핀 제제

Country Status (31)

Country Link
US (1) US10744132B2 (https=)
EP (1) EP3512518B1 (https=)
JP (1) JP6929367B2 (https=)
KR (1) KR102244500B1 (https=)
CN (1) CN109789137B (https=)
AR (1) AR110468A1 (https=)
AU (1) AU2017325910B2 (https=)
BR (1) BR112019004923A2 (https=)
CA (1) CA3033046C (https=)
CL (1) CL2019000624A1 (https=)
CO (1) CO2019003632A2 (https=)
DK (1) DK3512518T3 (https=)
ES (1) ES2934721T3 (https=)
FI (1) FI3512518T3 (https=)
HR (1) HRP20230062T8 (https=)
HU (1) HUE060906T2 (https=)
LT (1) LT3512518T (https=)
MX (1) MX374304B (https=)
MY (1) MY196269A (https=)
PE (1) PE20190707A1 (https=)
PH (1) PH12019500466A1 (https=)
PL (1) PL3512518T3 (https=)
PT (1) PT3512518T (https=)
RS (1) RS63894B1 (https=)
RU (1) RU2747306C2 (https=)
SG (1) SG11201901294QA (https=)
SI (1) SI3512518T1 (https=)
SM (1) SMT202300006T1 (https=)
TW (1) TWI743193B (https=)
WO (1) WO2018050043A1 (https=)
ZA (1) ZA201900890B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057075C (zh) * 1997-09-10 2000-10-04 中国石油化工总公司 低碳烯烃直接水合连续生产低碳醇的方法
BR112020016576A2 (pt) 2018-05-11 2020-12-15 Alar Pharmaceuticals Inc. Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina
KR102898979B1 (ko) * 2018-12-27 2025-12-10 에일러 파마슈티컬스 아이엔씨. 주사가능한 날트렉손 서방형 약학 제제
EP3936112A1 (en) * 2020-07-07 2022-01-12 Occlugel Hydrophilic degradable microspheres for delivering buprenorphine
IL308211A (en) * 2021-05-05 2024-01-01 Lyndra Therapeutics Inc Gastric residence systems comprising methadone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO121631B1 (ro) 1999-08-27 2008-01-30 Southern Research Institute Compoziţie cu buprenorfină şi utilizarea acesteia pentru reducerea consumului de heroină şi/sau alcool
DE60329515D1 (de) 2002-10-25 2009-11-12 Euro Celtique Sa Analoga und prodrugs von buprenorphin
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
TWI226830B (en) * 2002-11-12 2005-01-21 Chi Mei Foundation Medical Ct Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgesic pharmaceutical compositions
DE60224288T2 (de) 2002-11-25 2009-04-16 Chi Mei Foundation Medical Center Buprenorphinesterderivate, Verfahren zu ihrer Herstellung, und langwirksame analgetische Arzneimittel
WO2005117830A1 (en) 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
RU2008124805A (ru) * 2005-11-21 2009-12-27 Шеринг-Плоу Лтд. (CH) Фармацевтические композиции, содержащие бупренорфин
GB0606124D0 (en) 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
ES2549115T3 (es) * 2006-09-22 2015-10-23 Zynerba Pharmaceuticals, Inc. Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations

Also Published As

Publication number Publication date
US10744132B2 (en) 2020-08-18
FI3512518T3 (fi) 2023-01-31
PE20190707A1 (es) 2019-05-17
RU2019102895A (ru) 2020-08-03
TWI743193B (zh) 2021-10-21
ZA201900890B (en) 2021-08-25
WO2018050043A1 (en) 2018-03-22
CN109789137B (zh) 2023-01-13
PH12019500466A1 (en) 2020-01-20
SMT202300006T1 (it) 2023-03-17
AR110468A1 (es) 2019-04-03
LT3512518T (lt) 2023-02-10
TW201821077A (zh) 2018-06-16
AU2017325910A1 (en) 2019-02-21
MY196269A (en) 2023-03-24
DK3512518T3 (da) 2023-01-30
ES2934721T3 (es) 2023-02-24
EP3512518A1 (en) 2019-07-24
MX374304B (es) 2025-03-06
KR20190052021A (ko) 2019-05-15
BR112019004923A2 (pt) 2019-06-04
NZ750367A (en) 2021-01-29
RS63894B1 (sr) 2023-02-28
PL3512518T3 (pl) 2023-03-27
SG11201901294QA (en) 2019-03-28
JP6929367B2 (ja) 2021-09-01
RU2747306C2 (ru) 2021-05-04
MX2019002675A (es) 2019-08-01
AU2017325910B2 (en) 2020-08-27
RU2019102895A3 (https=) 2020-12-01
US20190142823A1 (en) 2019-05-16
EP3512518B1 (en) 2022-10-26
SI3512518T1 (sl) 2023-04-28
PT3512518T (pt) 2023-01-27
HUE060906T2 (hu) 2023-04-28
CN109789137A (zh) 2019-05-21
CO2019003632A2 (es) 2019-06-28
CL2019000624A1 (es) 2019-06-14
CA3033046A1 (en) 2018-03-22
JP2019529543A (ja) 2019-10-17
EP3512518A4 (en) 2020-06-03
HRP20230062T8 (hr) 2023-04-14
CA3033046C (en) 2021-09-07
HRP20230062T1 (hr) 2023-03-31

Similar Documents

Publication Publication Date Title
KR102244500B1 (ko) 서방형 부프레노르핀 제제
KR102839314B1 (ko) 오래 지속되는 주사용 제제와 부프레노핀 유도체
AU2019416507B2 (en) Naltrexone injectable sustained release formulation
US8455508B2 (en) Sustained release parenteral formulations of buprenorphine
HK40004794B (en) Sustained-release buprenorphine formulations
HK40004794A (en) Sustained-release buprenorphine formulations
NZ750367B2 (en) Sustained-release buprenorphine formulations
RU2806817C2 (ru) Инъекционная композиция налтрексона с замедленным высвобождением
HK40047988A (en) Naltrexone injectable sustained release formulation
US20220096460A1 (en) Abuse-resistant long-acting release opioid prodrugs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190329

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200911

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20200911

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201028

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210215

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201028

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210215

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20201223

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200911

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210416

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210315

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210215

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20201223

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200911

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210420

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210420

End annual number: 3

Start annual number: 1

PG1601 Publication of registration